Oncology Pharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONPH research report →
About the company
Oncology Pharma Inc. is a pharmaceutical firm specializing in oncology, dedicated to the development, manufacturing, and commercialization of therapeutic agents. The company has a collaborative and licensing agreement with Kalos Therapeutics Inc.
- CEO
- George Malesek
- IPO
- 1994
- Employees
- 1
- HQ
- San Francisco, CA, US
Price Chart
- Market Cap
- $1.37M
- P/E
- 502.00
- P/S
- 0.00
- P/B
- 3.31
- EV/EBITDA
- -349.31
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1.08%
- ROIC
- -0.30%
- Revenue
- $0 · 0.00%
- Net Income
- $-5,820 · 0.00%
- EPS
- $0.00 · 0.00%
- Op Income
- $-5,820
- FCF YoY
- 0.00%
- 52W High
- $0.36
- 52W Low
- $0.00
- 50D MA
- $0.07
- 200D MA
- $0.03
- Beta
- -4.43
- Avg Volume
- 31.67K
Get TickerSpark's AI analysis on ONPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ONPH coverage
Recent articles, reports, and earnings notes.
No research on ONPH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ONPH report →Similar companies
Peers in the same neighborhood.